2022 American Society of Hematology Annual (ASH) meeting published that the universal CD7 CART edited by CRISPR/Cas9 could effectively proliferate and specifically kill T-ALL tumor cells in vitro (44). This evidence concerns the gene CD7 and neoplasm.